UNICYCIVE THERAPEUTICS, INC. Stock-Based Compensation
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Stock-Based Compensation of $3.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- UNICYCIVE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.88M, a 403.85% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $754.00K, a 33.93% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $777.00K, a 33.51% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $730.00K, a 20.66% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $2.64M, a 12.38% increase from fiscal 2024.
- UNICYCIVE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $2.35M, a 32.99% increase from fiscal 2023.
- UNICYCIVE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $1.77M, a 68.77% increase from fiscal 2022.
- UNICYCIVE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $1.05M, a 8.39% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $3.63M 10-Q · filed 2026-08-12 | $4.41M derived: sum of 3 quarters · filed 2026-08-12 | $5.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $754.00K 10-Q · filed 2026-05-12 | $1.53M derived: sum of 2 quarters · filed 2026-05-12 | $2.26M derived: sum of 3 quarters · filed 2026-05-12 | $2.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $777.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.51M derived: sum of 2 quarters · filed 2026-03-30 | $2.08M derived: sum of 3 quarters · filed 2026-08-12 | $2.64M 10-K · filed 2026-03-30 |
| 2025-09-30 | $730.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.30M derived: sum of 2 quarters · filed 2026-08-12 | $1.86M 10-Q · filed 2025-11-12 | $2.45M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $571.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.13M 10-Q · filed 2026-08-12 | $1.72M derived: sum of 3 quarters · filed 2026-08-12 | $2.32M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $563.00K 10-Q · filed 2026-05-12 | $1.15M derived: sum of 2 quarters · filed 2026-05-12 | $1.75M derived: sum of 3 quarters · filed 2026-05-12 | $2.39M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $582.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.19M derived: sum of 2 quarters · filed 2026-03-30 | $1.83M derived: sum of 3 quarters · filed 2026-03-30 | $2.35M 10-K · filed 2026-03-30 |
| 2024-09-30 | $605.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.25M derived: sum of 2 quarters · filed 2025-11-12 | $1.77M 10-Q · filed 2025-11-12 | $2.32M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $641.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.16M 10-Q · filed 2025-08-14 | $1.71M derived: sum of 3 quarters · filed 2025-08-14 | $2.64M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $522.00K 10-Q · filed 2025-05-14 | $1.07M derived: sum of 2 quarters · filed 2025-05-14 | $2.00M derived: sum of 3 quarters · filed 2025-05-14 | $2.15M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $550.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.48M derived: sum of 2 quarters · filed 2025-03-31 | $1.62M derived: sum of 3 quarters · filed 2025-03-31 | $1.77M 10-K · filed 2025-03-31 |
| 2023-09-30 | $929.00K 10-Q · filed 2023-11-14 | $1.07M derived: sum of 2 quarters · filed 2024-08-14 | $1.22M 10-Q · filed 2024-11-13 | $1.41M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-06-30 | $144.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $288.00K 10-Q · filed 2024-08-14 | $485.00K derived: sum of 3 quarters · filed 2024-08-14 | $751.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $144.00K 10-Q · filed 2024-05-13 | $341.00K derived: sum of 2 quarters · filed 2024-05-13 | $607.00K derived: sum of 3 quarters · filed 2024-05-13 | $901.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $463.00K derived: sum of 2 quarters · filed 2024-03-28 | $757.00K derived: sum of 3 quarters · filed 2024-03-28 | $1.05M 10-K · filed 2024-03-28 |
| 2022-09-30 | $266.00K 10-Q · filed 2023-11-14 | $560.00K derived: sum of 2 quarters · filed 2023-11-14 | $850.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $294.00K 10-Q · filed 2022-11-14 | $584.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $290.00K 10-Q · filed 2023-05-16 | |||
| 2021-12-31 | $966.00K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $239.00K 10-Q · filed 2022-11-14 | $533.00K derived: sum of 2 quarters · filed 2022-11-14 | $735.00K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $294.00K 10-Q · filed 2022-11-14 | $496.00K 10-Q · filed 2021-08-16 | ||
| 2021-03-31 | $202.00K 10-Q · filed 2022-11-14 | |||
| 2020-09-30 | $71.00K 10-Q · filed 2021-11-12 | $131.00K derived: sum of 2 quarters · filed 2021-11-12 | $162.00K derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $60.00K 10-Q · filed 2021-11-12 | $91.00K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $31.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |